PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it displays a valid OMB control number Paperwork Reduction Act of 1995, no persons **Application Number ETHIBEM TRANSMITTAL** Filing Date **FORM** First Named Inventor Art Unit (to be used for all correspondence after initial filing) **Examiner Name** MICHELLE GRAFFED Attorney Docket Number 08/18/2003 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to Group X Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please **Terminal Disclaimer** Extension of Time Request Identify below): REPLY TO OFFICE ALTION Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm F. DECHANT or Individual Signature

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Typed or printed

Signature

Date

.

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

OIPE 430 / 642, 549
FEB 1 5 2006 May 13, 2004

Dr T.M. Baker The Permanente Medical Group 2345 Fair Oaks Blvd Sacramento, CA 95825

Dear Dr. Baker,

In a belated response to your letter of April 16, I would like to thank you for your concern.

At the present time there is no indication of a tumor on my scalp., and I do not wish to have An operation. You have made it clear that you have placed no credence in what I had to say about the tumor, about my composition for cancer treatment, and about my treatise concerning cancer.

I do want repeat what occurred three days after you took the biopsy specimen. A swelling in my scalp adjacent to my left ear occurred which was not painful until touched. My inner ear also became painful. What had occurred may not have been a metastasis but was equivalent to one, since virulent cancer cell(s) were released into my bloodstream. Had it not been for my composition that I mentioned to you, I would now be having chemotherapy and radiation treatment. As it turned out the pain subsided after two applications of my composition.

Richard Decharet

MSDS Number: R3900 * * * * * * Effective Date: 02/18/03 * * * * * Supercedes: 04/04/00

FEB 1 5 2006

Material Safety Data Sheet

From: Mailinckrodt Baker, Inc. 222 Red School Lane Phillipsburg, NJ 08865





24 Hour Emergency Telephone 908-859-2151 CHEMTREC: 1-880-424-9300

Mational Response in Canada CANUTEC: \$13.006.6669

Outside U.S. and Canada Chemitrec: 703-527-3687

HOTE: CHEMTREC, CANUTED and National Response Certer emergency numbers to be eased only to the event of chemical emergencies myolymg a spin leak, hre, exposure or not cost emotiving anonycals

All non-emergency quastions should be directed to Customer Service (1-800-592-2537) for assistance

RESORCINOL

1. Product Identification

Synonyms: Resorcin; 1-3 Dihydroxybenzene; m-Benzenediol; 1,3-Benzenediol

CAS No.: 108-46-3

Molecular Weight: 110.11 Chemical Formula: C6H6O2

Product Codes:

J.T. Baker: 3360, 3366, 3368

Mallinckrodt: 7232

. Composition/Information on Ingredients

Ingredient CAS No Percent Hazardous Resorcinol 108-46-3 90 - 100% Yes

. Hazards Identification

Emergency Overview

DANGER! MAY BE FATAL IF SWALLOWED. HARMFUL IF INHALED OR ABSORBED THROUGH SKIN. MAY CAUSE METHEMOGLOBINEMIA. AFFECTS CARDIOVASCULAR SYSTEM, CENTRAL NERVOUS SYSTEM, BLOOD, SPLEEN, LIVER AND KIDNEYS. CAUSES SEVERE IRRITATION TO SKIN AND EYES. CAUSES IRRITATION TO RESPIRATORY TRACT. MAY CAUSE ALLERGIC SKIN REACTION.

J.T. Baker SAF-T-DATA^(tm) Ratings (Provided here for your convenience)

Health Rating: 2 - Moderate
Flammability Rating: 1 - Slight
Reactivity Rating: 1 - Slight
Contact Rating: 2 - Moderate

Lab Protective Equip: GOGGLES; LAB COAT; VENT HOOD; PROPER GLOVES

Storage Color Code: Orange (General Storage)

Potential Health Effects

Inhalation:

Inhalation of dust causes irritation to respiratory tract. Toxic effects may follow and include methemoglobinemia, convulsions, and death.

Ingestion:

Toxic! A poison to blood and nerves. Causes gastrointestinal upset with severe diarrhea, sweating, weakness, headache, dizziness, cyanosis, spleen damage, kidney damage, cardiovascular effects, liver damage, and possibly convulsions and death.

Skin Contact:

Strong irritant to skin, causing severe dermatitis and loss of superficial layers of skin. Can be absorbed through skin with severe exposures producing symptoms paralleling ingestion and enlargement of local lymph glands. May cause allergic skin reactions.

Eve Contact:

Strong irritant. Can cause permanent damage.

Chronic Exposure:

Target organs include liver and kidneys.

Aggravation of Pre-existing Conditions:

Persons with pre-existing disorders of the blood, skin, liver, kidneys or lungs may be at an increased risk from exposure.

4. First Aid Measures

Inhalation:

Remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention immediately.

Ingestion:

If swallowed, give large quantities of water to drink and get medical attention immediately. Never give anything by mouth to an unconscious person.

Skin Contact:

Immediately flush skin with plenty of soap and water for at least 15 minutes while removing

10/642,549

The Permanente Medical Group, Inc.

2345 FAIR OAKS BOULEVARD SACRAMENTO, CALIFORNIA 95625 (916) 973-5000



RANCHO CORDOVA REDWOOD CITY RICHMOND ROSEVILLE SACRAMENTO SAN FRANCISCO SAN JOSE SAN RAFAEL SANTA CLARA SANTA ROSA S. SACRAMENTO S. SAN FRANCISCO STOCKTON VACAVILLE VALLEJO WALNUT CREEK

April 16, 2004

Mr Richard Dechant 500 Dunbarton Circle Sacramento, CA 95825

Dear Mr. Dechant:

I am writing this letter regarding our discussion in clinic on April 12, 2004. As we discussed, your scalp biopsy demonstrated a sclerosing or morpheaform basal cell carcinoma, which has a tendency to aggressively infiltrate the surrounding tissue. Although this type of cancer does not typically metastasize, it can be quite destructive locally. If left in place, it does have the ability to invade the adjacent structures, such as muscle and skull, and, given enough time, it could lead to significant health problems and even death. I respect your right to decide against any surgical treatment, but I urge you to reconsider. The surgery would only involve an approximately 45-60 minute procedure performed under a local anesthetic and would require no time in the hospital. If you change your mind regarding this issue, please contact us to arrange for surgery at (916) 631-3010. Regardless of your decision, I would like to see you back in approximately 6 months for a routine skin examination to check for any new skin cancers.

Sincerely,

Timothy M. Baker, MD